Stockscreener 앱 받기
49.98
1.81%
0.89
시장 영업 전:
49.98
전일 마감가:
$49.09
열려 있는:
$48.9
하루 거래량:
315.58K
Relative Volume:
0.65
시가총액:
$3.56B
수익:
$751.00K
순이익/손실:
$-74.57M
주가수익비율:
-45.31
EPS:
-1.1031
순현금흐름:
$-55.52M
1주 성능:
+0.30%
1개월 성능:
+2.44%
6개월 성능:
+162.22%
1년 성능:
+150.65%
1일 변동 폭
$47.31
$50.32
1주일 범위
$47.31
$51.26
52주 변동 폭
$12.56
$58.90
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, RMD, MDLN, ALC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
49.98 | 3.68B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
415.41 | 138.47B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
182.75 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
226.73 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.74 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.13 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Mizuho | Outperform |
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation (NASDAQ:PLSE) - Seeking Alpha
Precision Trading with Pulse Biosciences Inc (PLSE) Risk Zones - Stock Traders Daily
Pulse Biosciences stock reports 100 patient trial milestone - AD HOC NEWS
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - benzinga.com
BTIG initiates Pulse Biosciences stock coverage with buy rating By Investing.com - Investing.com Australia
BTIG Initiates Pulse Biosciences at Buy With $70 Price Target - Yahoo Finance
BTIG Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $70 - Moomoo
BTIG initiates coverage of Pulse Biosciences with Buy rating, $70 price target - TradingView
PLSE Initiated by BTIG -- Price Target Set at $70.00 - GuruFocus
Is Pulse Biosciences (PLSE) Fully Valued As Its Thyroid Trial Reaches 100 Patients? - Simply Wall Street
Pulse Biosciences, Inc (PLSE) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings Amidst Volatile Market Conditions - DirectorsTalk Interviews
Pulse Biosciences Launches New ATM Equity Program - theglobeandmail.com
Pulse Biosciences (NASDAQ: PLSE) Launches $85M ATM Offering at $54.21 Per Share - Kalkine Media
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com - Investing.com Australia
Pulse Biosciences Opens New $85 Million At-the-Market Stock Offering - Minichart
Pulse Biosciences enters $85 million equity distribution agreement with Mizuho - Investing.com
Pulse Biosciences completes enrollment in thyroid nodule study By Investing.com - Investing.com Nigeria
Pulse Biosciences Finalizes Enrollment for PRECISE-BTN Trial Evaluating nPulse Vybrance System - Kalkine Media
Pulse Biosciences Completes Enrollment In The PRECISE-BTN Clinical Study Evaluating The nPulse Vybrance Percutaneous Electrode System For Symptomatic Benign Thyroid Nodules - marketscreener.com
Pulse Biosciences (PLSE) Advances PRECISE-BTN Trial as Valuation Reflects High Growth Expectations - GuruFocus
Pulse Biosciences completes enrollment in thyroid nodule study - Investing.com
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules - Business Wire
Why is Pulse Biosciences stock surging today? By Investing.com - Investing.com Nigeria
Pulse Biosciences stock hits all-time high at 56.15 USD By Investing.com - Investing.com Nigeria
Freedom Capital initiates Pulse Biosciences stock with buy rating By Investing.com - Investing.com Australia
Why Pulse Biosciences Stock Popped Today - theglobeandmail.com
Freedom Capital Markets Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $73 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pulse Biosciences stock hits all-time high at 56.15 USD - Investing.com India
$Pulse Biosciences (PLSE.US)$ the squeeze is onnnnnnnn - Moomoo
PLSE Initiates Coverage by Freedom Capital Markets -- Price Targ - GuruFocus
Freedom Capital initiates Pulse Biosciences stock with buy rating - investing.com
PLSE Q2 2026 Earnings: Narrower-Than-Expected Loss Yields 1.96% Surprise But Shares DeclineEPS Miss Report - careplusvn.com
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pulse Biosciences Stock Price Forecast. Should You Buy PLSE? - StockInvest.us
Pulse Biosciences stock holds steady as investors eye recent clinical and financial progress - AD HOC NEWS
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Pulse Biosciences Inc (DE) (PLSE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com - Investing.com Australia
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock - Investing.com India
COO pays nearly $50 a share for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences Inc (DE) (PLSE) Peer Comparison – Compare with Others - Value Research
$Pulse Biosciences (PLSE.US)$ New ATH 🔥 - Moomoo
Pulse Biosciences Reports Teplitsky Liane Rae as New Insider COO - Kalkine Media
Pulse Biosciences stock hits new high as insider buying fuels rally - AD HOC NEWS
Pulse Biosciences stock hits all-time high at 51.0 USD - Investing.com
Pulse Biosciences stock hits all-time high at 51.0 USD By Investing.com - Investing.com Canada
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
펄스 바이오 주식 (PLSE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 31 '26 |
Buy |
48.80 |
1,024 |
49,971 |
3,094 |
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 28 '26 |
Buy |
48.35 |
1,034 |
49,994 |
2,070 |
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 26 '26 |
Buy |
48.23 |
1,036 |
49,971 |
1,036 |
| LAVIOLETTE PAUL A | Chief Executive Officer |
May 11 '26 |
Buy |
19.69 |
15,000 |
295,350 |
15,000 |
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
0.82%
0.26%
자본화:
|
볼륨(24시간):